2250292-39-6
2250292-39-6 structure
- Name: Pavurutamab
- Chemical Name: Pavurutamab
- CAS Number: 2250292-39-6
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Cancer
- Create Date: 2023-05-19 23:55:48
- Modify Date: 2024-12-04 19:08:27
-
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM)[1][2][3][4].
| Name | Pavurutamab |
|---|
| Description | Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM)[1][2][3][4]. |
|---|---|
| Related Catalog | |
| Target |
B cell maturation antigens, BCMA[1] |
| In Vitro | Pavurutamab (0-10000 pM；48 h) 诱导 CD69+、CD25+ T 细胞活化和 IFNγ、TNFα、IL-2、IL-4、IL-6、IL-10 细胞因子分泌[5]。 |
| In Vivo | Pavurutamab (0.02、0.2 和 2 mg/kg；静脉注射；第 3、8、13 天单剂量) 在小鼠异种移植模型中以时间和剂量依赖的方式减少肿瘤体积[5]。 Pavurutamab (0.005、0.05 和 0.5 mg/kg；静脉注射；每 5 天给药 6 次，持续 30 天) 在移植 L-363 多发性骨髓瘤 (MM) 细胞的 NOD/SCID 小鼠中，以时间和剂量依赖的方式减少肿瘤体积并提高存活率[5]。 Animal Model: Female NOD/SCID mice transplanted with NCI-H929 MM cells mixed with PBMCs[5]. Dosage: 0.02, 0.2 and 2 mg/kg. Administration: Intravenous injection; single dose on days 3, 8, 13. Result: Reduced tumor volume. Animal Model: NOD/SCID mice orthotopically transplanted with L-363 MM cells[5]. Dosage: 0.005, 0.05 and 0.5 mg/kg. Administration: Intravenous injection; every 5 days for 6 administrations, starting from day 9 and lasting for 30 days. Result: Reduced tumor volume and increased survival. |
| References |
| No Any Chemical & Physical Properties |